Ossium Health

cell therapy, deceased donor stem cells, bioengineering

replacementreplacingcell therapy

ossiumhealth.com·San Francisco, California, United States; Indianapolis, Indiana, United States·Founded 2016·Series C Plus·$115M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-OKVU

Summary · Eternal Search editorial

Ossium Health cell therapy, deceased donor stem cells, bioengineering

Ossium Health says its mission is to improve human health, vitality, and longevity through bioengineering. The company has built a platform around the deceased donor transplant ecosystem to develop cell therapies for diseases of the blood and immune systems. Its pipeline includes HPC, Marrow for hematologic malignancies and OssiGraft viable bone matrix allografts for musculoskeletal defects.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite31

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Ossium Health — Translational · Lower middle. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.

Source: Deterministic

At a glance

Webossiumhealth.com

HQSan Francisco, California, United States; Indianapolis, Indiana, United States

Founded2016

StageSeries C Plus

Publications

20 on file

012026Hematopoietic stem cells from organ donors lead to long-term multi-lineage engraftment in NSG mice—→022026Development and validation of a potency assay matrix for optimized and consistent manufacture of clinical mesenchymal stem/stromal cells—→032026Editorial: Potency assays for use in manufacturing cellular immunotherapies.Frontiers in immunology→042026Cryopreserved organ donor bone marrow achieves robust engraftment and chimerism in mismatched allogeneic transplantation.Cytotherapy→052026Development and validation of a potency assay matrix for optimized and consistent manufacture of clinical mesenchymal stem/stromal cells.Frontiers in immunology→062026Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor.Blood advances→072026Hematopoietic stem cells from organ donors lead to long-term multi-lineage engraftment in NSG mice.Bone marrow transplantation→082026Single cell transcriptional profiling of monocytes from asthma patients show a predisposition for an inflammatory response.Cytotherapy→092025Reversing coma by senolytics and stem cells: the future is now.Journal of translational medicine→102025Barriers to Effective Cryopreservation of Cell Therapies: Challenges and Emerging Solution.Advances in experimental medicine and biology→112025Allogenic Vertebral Body Adherent Mesenchymal Stromal Cells Promote Muscle Recovery in Diabetic Mouse Model of Limb Ischemia.Annals of vascular surgery→122024Unraveling the Enigma of Organismal Death: Insights, Implications, and Unexplored Frontiers.Physiology (Bethesda, Md.)→132023Accelerating cryoprotectant delivery using vacuum infiltration.Cryobiology→142023Characterization and Function of Cryopreserved Bone Marrow from Deceased Organ Donors: A Potential Viable Alternative Graft Source.Transplantation and cellular therapy→152023Identification of a fundamental cryoinjury mechanism in MSCs and its mitigation through cell-cycle synchronization prior to freezing.Cryobiology→162021A Large-Scale Bank of Organ Donor Bone Marrow and Matched Mesenchymal Stem Cells for Promoting Immunomodulation and Transplant Tolerance.Frontiers in immunology→172020Identification and characterization of a large source of primary mesenchymal stem cells tightly adhered to bone surfaces of human vertebral body marrow cavities.Cytotherapy→182020Ischemia considerations for the development of an organ and tissue donor derived bone marrow bank.Journal of translational medicine→192017The promise of organ and tissue preservation to transform medicine.Nature biotechnology→202016Community crystal gazing.Nature biotechnology→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Ossium Health

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.